1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Urinary Tract Infection Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Urinary Tract Infection Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • December 2021
  • 112 pages
  • ID: 6192753
  • Format: PDF
  • Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

The Urinary Tract Infection Therapeutics Market is expected to register a CAGR of 4.1% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.

Key Highlights
According to a study published in Advances in Urology 2018, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20–49 years. Moreover, during a lifetime, approximately 7% of women and 13% of men will develop a kidney stone.
Therefore, with the increasing prevalence of diabetes and kidney stones, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs, thus, driving the global urinary tract infection therapeutics market.
Additionally, the launch of more efficient combination drugs and increasing geriatric population are expected to boost the growth of the urinary tract infection therapeutics market.
However, according to the Center for Education & Research on Therapeutics, over 2 million cases of adverse drug reactions (ADRs) are reported every year, leading to approximately 100,000 deaths.
According to the FDA, it is estimated that, in the United States, each year, over 350,000 ADRs occur in nursing homes alone.
With an increase in the number of cases of ADRs being reported, globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
Additionally, the lack of awareness about the prevalence of UTIs in the developing and underdeveloped countries is also restraining the growth of the market.

Key Market Trends

Complicated UTIs Segment is Expected to Hold a Major Market Share in the Urinary Tract Infection Therapeutics Market

The prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases.

According to the American Academy of Family Physicians (AAFP), kidney stones are a common disorder, with an annual incidence of eight cases per 1,000 adults. Moreover, around 13% of men and 7% of women develop a kidney stone in their lifetime and the overall incidence of urinary retention is 4.5 to 6.8 per 1,000 men, per year, in the United States. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States.

Furthermore, According to the Queensland Pediatric Factsheet 2019, estimates that approximately 1 in 10 girls and 1 in 50 boys will suffer from a urinary tract infection by seven years of age. Infections in children under one year are more common in boys but in older children infections are more common in girls. Thus, owing to the above factors the market is expected to show growth in the coming years.

Competitive Landscape

The urinary tract infection therapeutics market is fragmented competitive and consists of a number of major players. Some of the companies which are currently dominating the market are AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Shionogi & Co., Ltd, Novartis AG, and Pfizer, and others.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Genito-Urinary Drugs Global Market Report 2022

  • $ 5000
  • March 2022
  • 300 pages

Major companies in the genito-urinary drugs market include Sanofi S.A., GlaxosmithKline, AstraZeneca, AbbVie, Reckitt , Benckiser Group plc., Astellas Pharma Inc., Otsuka Holdings Co. ltd., Pfizer Inc., ...

  • World
  • Middle East
  • Pharmaceutical
  • Incontinence Product
  • Industry analysis
  • Health Expenditure

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on